Skip to content

Released Feb 26, 2019, after the close

10-K filed Feb 26, 2019, 57 days after period end · 0001232524-19-000013

Q4 2018 · 10-K
Revenue$476.46M+9.2% vs Q4 2017+1.5% vs Q3 2018
Net Income$159.47M−31.3% vs Q4 2017+6.8% vs Q3 2018
EPS Diluted$2.64−30.3% vs Q4 2017+9.5% vs Q3 2018
Gross Profit$440,997,000+8.9%
Operating Incomederived$185,055,000+31.1%
Operating Cash Flowderived$218,096,000+6.6%
Free Cash Flowderived$212,947,000+8.8%
Margins · derived
Gross margin92.6%−0.2 pt vs Q4 2017
Operating margin38.8%+6.5 pt vs Q4 2017
Net margin33.5%−19.7 pt vs Q4 2017

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2018Q4 2017Q4 2016Q4 2015
Revenue$476.46M$436.40M$396.62M$340.88M
Net Income$159.47M$232.21M$116.69M$82.76M
EPS Diluted$2.64$3.79$1.91$1.32

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR